Status:
COMPLETED
Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia
Lead Sponsor:
Fang Luo
Conditions:
Restlessness
Pain
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Dexmedetomidine is a highly selective α2 adrenoreceptor agonist approved by the US FDA for short-term postoperative sedation and analgesia.It can also reduce the stress response without respiratory de...
Detailed Description
Dexmedetomidine can significantly reduce the emergence agitation and postoperative pain in patients who received chest surgery
Eligibility Criteria
Inclusion
- American Society of Anaesthesiologists Physical Status (ASA-PS) I or II
- undergoing selective thoracotomy
- weight between 45 and 75kg
- operation time 2-4 hours
Exclusion
- history of neurologic disease
- history of chronic analgesics intake
- history of allergic reactions to the experimental durgs
- history of renal insufficiency
- history of hepatic dysfunction
- history of coagulation disorders
- women in lactation
- participating in other studies
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01517932
Start Date
June 1 2011
End Date
December 1 2011
Last Update
March 20 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.